ChemoCentryx Inc (CCXI) Q1 2021 Earnings Call Transcript Motley Fool Transcribers © The Motley Fool Logo of jester cap with thought bubble.
ChemoCentryx Inc (NASDAQ: CCXI)
Operator
Good day and thank you for standing by. Welcome to the ChemoCentryx First Quarter 2021 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today s conference is being recorded. [Operator Instructions]
I would now like to hand the conference over to Lee Roth of Burns McClellan. Please go ahead, sir.SPONSORED:
10 stocks we like better than ChemoCentryx
Free Webinar with Joe Schwartz | NewsRadio WINA
wina.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wina.com Daily Mail and Mail on Sunday newspapers.
Free Webinar with Joe Schwartz
3wv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from 3wv.com Daily Mail and Mail on Sunday newspapers.
Free Webinar with Joe Schwartz | WVAX-AM 1450
wvax.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wvax.com Daily Mail and Mail on Sunday newspapers.
Shares of Solid Biosciences (
SLDB) - Get Report dropped Tuesday after the developer of a Duchenne muscular-dystrophy treatment reported that a patient had an adverse event in an trial of its gene-therapy candidate.
The Cambridge, Mass., company said that six patients in its ongoing clinical study showed promising results.
A seventh patient was safely dosed, with transient and manageable adverse events, none of which were serious, it said in a statement The totality of data collected, and the reinitiation of dosing, support the continued enrollment of patients into the Ignite DMD study, the company said. We are encouraged with the successful resumption of dosing in the Ignite DMD trial under our amended clinical protocol and using SGT-001 manufactured with a second-generation process, Barry Byrne, a physician who is principal investigator of the study, said.